Olsson Ing-Marie, Malmström Marlene, Rydén Lisa, Olsson Möller Ulrika
Department of Health Sciences, Lund University, Lund, Sweden.
Skåne University Hospital, Malmö, Sweden.
J Multidiscip Healthc. 2022 May 10;15:1057-1068. doi: 10.2147/JMDH.S355055. eCollection 2022.
A substantial proportion of women with breast cancer (BC) experience a wide range of long-term persistent and troublesome side effects related to the disease and its treatment. The ReScreen randomized controlled trial is conducted aiming to evaluate the effect of early screening of distress followed by individualized rehabilitation after primary BC treatment.
To examine recruitment, retention, distribution of distress, relevance of intervention and reported problems in a pilot trial of the ReScreen RCT.
Based on international research, a cutoff of ≥7 on the Distress Thermometer was used to identify women in need of extended support. Those who reported high distress were randomized to intervention group (IG, n = 9) or control group (CG, n = 9), while women with low distress formed an observational group (OG, n = 67). Self-reported data was collected at baseline, 2 weeks and 3, 6, 9, and 12 months after start of treatment. The participants were recruited from a BC unit in Sweden. Descriptive statistics were used for analyses.
Eighty-five patients consented to participate. The recruitment rate was 73%, answer frequency was 98%, 64%, 95%, and retention rate was 100%, 56%, 91% in the IG, CG and OG, respectively. Few systematic errors were identified. When exploring the distribution of distress, it was evident that the participants scoring ≥7 were fewer (21.2%) than reported in previous studies (34-43%). The most commonly problems reported were in line with previous reports of symptoms, including fatigue and worry.
The satisfactory rates of inclusion and data collection and the few systematic errors indicate that the ReScreen study is feasible if well planned and executed. To identify patients in need of extended support, an adjustment of the cutoff in the main study is indicated. Based on self-reported problems, the intervention was found relevant in this context.
相当一部分乳腺癌(BC)女性经历了与疾病及其治疗相关的一系列长期持续且令人困扰的副作用。开展ReScreen随机对照试验旨在评估早期筛查痛苦并在原发性乳腺癌治疗后进行个体化康复的效果。
在ReScreen随机对照试验的一项试点试验中,研究招募情况、留存率、痛苦的分布、干预的相关性以及报告的问题。
基于国际研究,使用痛苦温度计得分≥7作为识别需要额外支持的女性的标准。报告高痛苦程度的患者被随机分为干预组(IG,n = 9)或对照组(CG,n = 9),而低痛苦程度的女性组成观察组(OG,n = 67)。在基线、治疗开始后2周以及3、6、9和12个月收集自我报告数据。参与者从瑞典的一个乳腺癌科室招募。采用描述性统计进行分析。
85名患者同意参与。招募率为73%,回答频率分别为98%、64%、95%,留存率在IG、CG和OG中分别为100%、56%、91%。几乎未发现系统误差。在探索痛苦的分布时,很明显得分≥7的参与者(21.2%)比先前研究报告的(34 - 43%)要少。报告的最常见问题与先前关于症状的报告一致,包括疲劳和担忧。
纳入率和数据收集的满意率以及极少的系统误差表明,如果计划和执行得当,ReScreen研究是可行的。为了识别需要额外支持的患者,表明在主要研究中需要调整临界值。基于自我报告的问题,发现该干预在此背景下是相关的。